NFL Biosciences, a clinical-stage biopharmaceutical company based in France, has confirmed that three of its research communications regarding drug candidates NFL-101 and NFL-102 have been selected for presentation at the upcoming SRNT-Europe 2026 conference. The Society for Research on Nicotine and Tobacco (SRNT) event serves as a primary forum for global experts to review advancements in smoking cessation treatments.
Scientific Focus on NFL-101 and NFL-102
The company’s presence at the 2026 conference centers on its specialized portfolio targeting nicotine addiction. According to official company disclosures, the accepted communications provide updated data on the mechanism of action and clinical development trajectory for their primary assets.
NFL-101 is a nicotine-free botanical drug candidate derived from tobacco leaf proteins. It is currently being studied as a smoking cessation aid. The research to be presented at SRNT-Europe will detail findings from recent clinical trials, focusing on the candidate’s ability to reduce cravings and withdrawal symptoms. NFL-102, meanwhile, represents the company’s newer development pipeline, focusing on pharmaceutical-grade nicotine agonists designed to support long-term abstinence.
Significance for the Smoking Cessation Market
The selection of these three abstracts for the SRNT-Europe 2026 program underscores the growing interest in non-nicotine-based therapeutic approaches. By presenting at this specific conference, NFL Biosciences aims to align its clinical data with the standards required by the international scientific community.
The SRNT-Europe organization facilitates the exchange of research between academic institutions and private pharmaceutical developers. For investors and stakeholders, the presentation of verified trial data at a peer-reviewed conference is often viewed as a checkpoint for the viability of late-stage clinical assets. The company has maintained that these presentations are intended to demonstrate the efficacy and safety profile of their candidates as they move toward potential regulatory filings.
Clinical Development Timeline and Next Steps
Following the presentations in 2026, NFL Biosciences is expected to utilize the feedback from the scientific community to refine its Phase 2 and Phase 3 trial designs. The company’s strategy involves leveraging these academic validations to support ongoing discussions with potential commercial partners and regulatory bodies.
While the company continues to report progress, it reminds shareholders and the public that clinical development remains subject to inherent risks. The results of past clinical trials or preliminary data do not guarantee success in subsequent, larger-scale studies. Decisions regarding the company’s financial outlook should be based on official regulatory filings and audited financial statements rather than interim conference presentations.
How to Follow Further Developments
The SRNT-Europe 2026 conference is scheduled to host researchers from across the globe, with the specific dates and venue for the NFL Biosciences sessions to be published on the official society website closer to the event. For real-time updates regarding clinical trial milestones, interested parties should monitor the official NFL Biosciences investor relations portal.
The company is expected to release a comprehensive summary of its conference findings following the conclusion of the event. These updates will provide the most accurate account of the data presented and the subsequent reception by the scientific panel.
